Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forma To Rev Its Discovery Engine For Deubiquitination

This article was originally published in The Pink Sheet Daily

Executive Summary

In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.

Advertisement

Related Content

Celgene Returns To Forma’s Door, This Time With Option To Buy
Deals of the Week: Is Botox On The Block?
With Celgene Deal, Forma Makes First Foray Into Clinical Development
New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
Forma To Play To Its Strengths WIth Genentech Deal
The Next Big Thing In Drug Development May Be The Ubiquitin Pathway

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel